GPT and chronic hepatitis C virus infection: The first pilot study on eleven patients with chronic hepatitis C receiving for 8-weeks 1.8 or 3.6 g/day bLf showed a decrease in serum alanine transaminase (ALT) and HCV RNA levels, suggesting that bLf could be efficient against HCV infections [170].